amantadine has been researched along with Huntington Disease in 22 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Huntington chorea, like levodopa-induced dyskinesias, may be responsive to amantadine hydrochloride treatment." | 9.10 | A randomized trial of amantadine in Huntington disease. ( Dewey, RB; O'Suilleabhain, P, 2003) |
| "Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months." | 7.65 | Treatment of involuntary movement disorders with tetrabenazine. ( Heathfield, KW; Roberts, AH; Swash, M; Zakko, H, 1972) |
| "Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36% (p = 0." | 5.10 | Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. ( Chase, TN; Farmer, C; Gillespie, M; Morris, MJ; Mosby, K; Verhagen Metman, L; Wuu, J, 2002) |
| "Huntington chorea, like levodopa-induced dyskinesias, may be responsive to amantadine hydrochloride treatment." | 5.10 | A randomized trial of amantadine in Huntington disease. ( Dewey, RB; O'Suilleabhain, P, 2003) |
| "If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit." | 3.78 | Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. ( Armstrong, MJ; Miyasaki, JM, 2012) |
| "Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months." | 3.65 | Treatment of involuntary movement disorders with tetrabenazine. ( Heathfield, KW; Roberts, AH; Swash, M; Zakko, H, 1972) |
| "Catatonia is an underdiagnosed psychomotor syndrome often associated with neurological and psychiatric disorders, but it has rarely been documented in patients with HD." | 1.37 | Westphal variant Huntington disease and refractory catatonia: a case report. ( Aguilar-Venegas, LC; Espinola-Nadurille, M; Fricchione, GL; Merida-Puga, J; Ramirez-Bermudez, J, 2011) |
| "Two patients with advanced Huntington's disease manifested a marked increase in irritability and aggressiveness when treated with amantadine during an epidemic of influenza." | 1.27 | Adverse behavioral effects of amantadine therapy in Huntington's disease. ( Stewart, JT, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (45.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Doher, N | 1 |
| Gupta, HV | 1 |
| Danysz, W | 1 |
| Dekundy, A | 1 |
| Scheschonka, A | 1 |
| Riederer, P | 1 |
| Merida-Puga, J | 1 |
| Ramirez-Bermudez, J | 1 |
| Aguilar-Venegas, LC | 1 |
| Fricchione, GL | 1 |
| Espinola-Nadurille, M | 1 |
| Armstrong, MJ | 1 |
| Miyasaki, JM | 1 |
| Verhagen Metman, L | 1 |
| Morris, MJ | 1 |
| Farmer, C | 1 |
| Gillespie, M | 1 |
| Mosby, K | 1 |
| Wuu, J | 1 |
| Chase, TN | 1 |
| Lucetti, C | 2 |
| Gambaccini, G | 2 |
| Bernardini, S | 2 |
| Dell'Agnello, G | 1 |
| Petrozzi, L | 1 |
| Rossi, G | 2 |
| Bonuccelli, U | 2 |
| Del Dotto, P | 1 |
| Dell' Agnello, G | 1 |
| Murri, L | 1 |
| Hersch, SM | 1 |
| O'Suilleabhain, P | 1 |
| Dewey, RB | 1 |
| Heckmann, JM | 1 |
| Legg, P | 1 |
| Sklar, D | 1 |
| Fine, J | 1 |
| Bryer, A | 1 |
| Kies, B | 1 |
| Qin, ZH | 1 |
| Wang, J | 1 |
| Gu, ZL | 1 |
| Bonelli, RM | 1 |
| Hofmann, P | 1 |
| Saran, BM | 1 |
| Klein, MS | 1 |
| Benay, EM | 1 |
| Gray, MW | 1 |
| Herzberg, L | 1 |
| Lerman, JA | 1 |
| Turnbull, MJ | 1 |
| Victoratos, G | 1 |
| Biéder, J | 1 |
| Stewart, JT | 1 |
| Scotti, G | 1 |
| Spinnler, H | 2 |
| Weiner, WJ | 1 |
| Klawans, HL | 1 |
| Swash, M | 1 |
| Roberts, AH | 1 |
| Zakko, H | 1 |
| Heathfield, KW | 1 |
| Candelise, L | 1 |
| Faglioni, P | 1 |
| Vignolo, LA | 1 |
| Schergna, E | 1 |
| Bird, MT | 1 |
| Paulson, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)[NCT00127114] | Phase 4 | 0 participants (Actual) | Interventional | 2005-09-30 | Withdrawn (stopped due to No funding and exclusion criteria were to stringent.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for amantadine and Huntington Disease
| Article | Year |
|---|---|
Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.
Topics: Amantadine; Diamond; Humans; Huntington Disease; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2021 |
Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
Topics: Amantadine; Anti-Dyskinesia Agents; Antiparkinson Agents; Eicosapentaenoic Acid; Fatty Acids, Unsatu | 2003 |
Development of novel therapies for Huntington's disease: hope and challenge.
Topics: Amantadine; Animals; Cell Transplantation; Drugs, Chinese Herbal; Humans; Huntingtin Protein; Huntin | 2005 |
A systematic review of the treatment studies in Huntington's disease since 1990.
Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Ag | 2007 |
6 trials available for amantadine and Huntington Disease
| Article | Year |
|---|---|
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
Topics: Adult; Aged; Amantadine; Chorea; Cognition; Cross-Over Studies; Dopamine Agents; Double-Blind Method | 2002 |
Amantadine in Huntington's disease: open-label video-blinded study.
Topics: Aged; Amantadine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Hunti | 2002 |
IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study.
Topics: Administration, Oral; Aged; Amantadine; Cross-Over Studies; Drug Administration Schedule; Excitatory | 2003 |
A randomized trial of amantadine in Huntington disease.
Topics: Amantadine; Chorea; Cross-Over Studies; Elbow; Female; Humans; Huntington Disease; Male; Mental Proc | 2003 |
IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study.
Topics: Adult; Amantadine; Behavior; Cross-Over Studies; Double-Blind Method; Female; Humans; Huntington Dis | 2004 |
Letter: Treatment of Huntington's chorea.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Clinical Trials as Topic; Dia | 1973 |
12 other studies available for amantadine and Huntington Disease
| Article | Year |
|---|---|
Paraneoplastic Chorea Managed with Intravenous Amantadine.
Topics: Amantadine; Chorea; Humans; Huntington Disease | 2019 |
Westphal variant Huntington disease and refractory catatonia: a case report.
Topics: Adult; Amantadine; Carbidopa; Catatonia; Combined Modality Therapy; Dopamine Agents; Drug Combinatio | 2011 |
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.
Topics: Adult; Amantadine; Anticonvulsants; Chorea; Evidence-Based Medicine; Humans; Huntington Disease; Ril | 2012 |
Clinical evaluation of amantadine and haloperidol in Huntington's chorea.
Topics: Amantadine; Drug Therapy, Combination; Haloperidol; Humans; Huntington Disease; Male | 1980 |
Letter: Amantadine in chorea.
Topics: Aged; Amantadine; Chorea; Drug Evaluation; Homovanillic Acid; Humans; Huntington Disease; Hydroxyind | 1975 |
[Cases of Huntington's chorea observed in a psychiatric setting: remarks on therapy].
Topics: Adult; Amantadine; Female; Humans; Huntington Disease; Male; Mental Disorders; Middle Aged; Penicill | 1975 |
Adverse behavioral effects of amantadine therapy in Huntington's disease.
Topics: Adult; Aggression; Amantadine; Humans; Huntington Disease; Influenza, Human; Male | 1987 |
Amantadine and Huntington's chorea.
Topics: Adult; Amantadine; Female; Humans; Huntington Disease; Male; Middle Aged | 1971 |
Amantadine in Huntington's chorea.
Topics: Amantadine; Caudate Nucleus; Dopamine; Humans; Huntington Disease; Receptors, Drug | 1972 |
Treatment of involuntary movement disorders with tetrabenazine.
Topics: Adolescent; Adult; Aged; Amantadine; Child; Depression; Dystonia Musculorum Deformans; Evaluation St | 1972 |
[Recent therapeutic conquests in extrapyramidal syndromes].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Amantadine; Athetosis; Brain Diseases; Central | 1970 |
The rigid form of Huntington's chorea.
Topics: Adult; Age Factors; Amantadine; Dihydroxyphenylalanine; Female; Humans; Huntington Disease; Movement | 1971 |